
Autobahn Therapeutics Raises $100 Million in Oversubscribed Series C for CNS Disorder Treatments
Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath…












